Answers are grounded in this paper and cite their sources.
Background Immune checkpoint inhibitors (ICIs) often induce immune-related adverse events (irAEs). A potentially fatal irAE is immune-related (ir) myositis and ir-myocarditis, particularly the ir-myositis-myocarditis-myasthenia overlap (ir-MMM). Evidence derives from trials, pharmacovigilance and specialist-centre series, leaving population-based incidence and phenotype-specific risk poorly defined. Patients and methods In a retrospective, population-based cohort, we included all adult patients with cancer treated with ICIs (anti-programmed cell death protein 1/anti-programmed death-ligand 1 and/or anti-cytotoxic T-lymphocyte-associated protein 4) in the Region of Southern Denmark from September 2013 to December 2024. Natural language processing of electronic health records and laboratory data identified potential cases, which were confirmed by expert adjudication. Patients were classified as having isolated ir-myositis, isolated ir-myocarditis or ir-myositis-myocarditis overlap; bulbar/ocular involvement defined ir-MMM. Primary outcomes were phenotype distribution and toxicity-related mortality. Results Among 2893 ICI-treated patients, 53 (1.8%) developed ir-myositis and/or ir-myocarditis: isolated ir-myositis in 13 of 53 (24%), isolated ir-myocarditis in 12 of 53 (23%), and overlap in 28 of 53 (53%), including 15 (28%) with ir-MMM. Five (9%) died of toxicity, all in the overlap group, and four of five (80%) had ir-MMM. Dyspnoea and bulbar/ocular symptoms were present in 100% and 80% of fatal cases. Median peak high-sensitivity cardiac troponin T (hs-cTnT) was nearly 10-fold higher in fatal (2540 ng/l) than in nonfatal cases (274 ng/l). Isolated ir-myositis caused no deaths but was long-lasting (92% experienced for >6 months). Conclusions Ir-myositis and/or ir-myocarditis occurred in ∼2% of ICI-treated patients. Mortality was confined to overlap, particularly ir-MMM, and was associated with dyspnoea, bulbar/ocular symptoms and markedly elevated hs-cTnT concentration, features not captured by Common Terminology Criteria for Adverse Events (CTCAE) grading. Our findings support phenotype-based risk stratification over CTCAE grading.
No takes yet. Share an insight, caveat, or question.
Tenstad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: